The Europe Human Microbiome Market would witness market growth of 31.7% CAGR during the forecast period (2022-2028). The increased focus on the development of human Microbiome treatment is driving the market growth. Human microbiomes have also established themselves as viable target for therapeutic research. The growing number of market player collaborations is likely to provide a diverse range of growth prospects for market players in the coming years. Moreover, the rising investment by various governments and market players on increasing the research and development activities for bringing developments in the field of human microbiomes. An aberrant immune reaction to body tissues is induced or triggered by the buildup of disease-causing germs. Autoimmune illnesses, intestinal inflammatory disease, as well as other life-threatening conditions are exacerbated by this. A balanced and systematic interplay develops over time due to the coevolution of the human microbiota and immune system. However, changes in the host-microbiota connection disrupt this interaction, resulting in impaired immune response and perhaps inflammatory disease. A disrupted mucus layer may compromise the intestine's barrier function, resulting in faulty cell linkage attachment. Increased levels of proinflammatory cytokines (IL12, IFN-) and decreased levels of anti-inflammatory cytokines (IL-10) are associated with a reduction in intestinal Firmicutes. In IBD-prone mice, several helminth infections were linked to anti-inflammatory organisms that prevented inflammatory bowel disease. There is a significant number of regional people that are consuming alcohol. According to the Eurostat, in 2019, 8.4% of EU adults consumed alcohol on a daily basis, 28.8% weekly, 22.8% monthly, while 26.2 % never consumed or had not consumed in the previous 12 months. Alcohol use has been reported to rise with age in the region. People aged 15 to 24 had the lowest proportion of those who consumed alcohol the most frequently (i.e. every day), while those aged 75 and over had the largest share (16.0%). However, the latter age group had the highest percentage (40.3%) of people who had never drunk alcohol or had not consumed any in the previous year. Weekly alcohol consumption was generally consistent throughout all age groups between 25 and 64, with people aged 45 to 54 having the highest share (33.5%). With age, monthly and less than monthly intake declined little. People aged 25 to 34 had the highest percentage of monthly alcohol consumption (28.5%). Men were more likely than women to use alcohol on a daily and weekly basis (respectively 13.0% of men vs. 4.1% of women and 36.4% of men vs. 21.7% of women). Heavy drinking is defined as consuming more than 60 grams of pure ethanol in a single sitting. Adults in the EU Member States reported heavy drinking episodes at least once a month in proportions ranging from 4% (Cyprus and Italy) to 38% (Denmark). The Germany market dominated the Europe Human Microbiome Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $72.6 million by 2028. The UK market is poised to grow at a CAGR of 30.6% during (2022 - 2028). Additionally, The France market would display a CAGR of 32.7% during (2022 - 2028). Based on Product, the market is segmented into Drugs, Diagnostic Tests, Probiotics, Prebiotics, and Others. Based on Disease Type, the market is segmented into Infectious Diseases, Endocrine & Metabolic Disorders, Gastrointestinal Diseases, Cancer, and Others. Based on Technology, the market is segmented into Genomics, Proteomics and Metabolomics. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on Type, the market is segmented into Microbiome Consortia Transplantation (FMT), Peptide, Live Biotherapeutic Product and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Seres Therapeutics, Inc., 4D pharma plc, OptiBiotix Health Plc, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., Ferring Holdings SA, and Enterome. Scope of the Study Market Segments covered in the Report: By Product ? Drugs ? Diagnostic Tests ? Probiotics ? Prebiotics, and ? Others By Disease Type ? Infectious Diseases ? Endocrine & Metabolic Disorders ? Gastrointestinal Diseases ? Cancer, and ? Others By Technology ? Genomics ? Proteomics ? Metabolomics By Application ? Therapeutics ? Diagnostics By Type ? Microbiome Consortia Transplantation (FMT) ? Peptide ? Live Biotherapeutic Product ? Others By Country ? Germany ? UK ? France ? Russia ? Spain ? Italy ? Rest of Europe Companies Profiled ? Seres Therapeutics, Inc. ? 4D pharma plc ? OptiBiotix Health Plc ? Synlogic, Inc. ? Second Genome, Inc. ? Vedanta Biosciences, Inc. ? Finch Therapeutics Group, Inc. ? Ferring Holdings SA ? Enterome Unique Offerings from KBV Research ? Exhaustive coverage ? Highest number of market tables and figures ? Subscription based model available ? Guaranteed best price ? Assured post sales research support with 10% customization free